- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Europe Viscosupplementation Market to Reach $869.8M by 2035
Driven by Outpatient Care Expansion and Innovative Treatments
Mar. 31, 2026 at 11:53am
Got story updates? Submit your updates here. ›
Innovative viscosupplementation treatments are reshaping joint care in Europe, offering patients new options for pain relief and mobility without the downtime of surgery.Newark TodayThe Europe viscosupplementation market is projected to grow from $523.9 million in 2025 to $869.8 million by 2035, driven by rising osteoarthritis prevalence, an aging population, and increasing adoption of non-surgical joint therapies. Advancements in hyaluronic acid formulations and the expansion of ambulatory surgical centers are fueling this market expansion.
Why it matters
As patients seek pain relief without the downtime of surgery, the viscosupplementation market in Europe is evolving to meet this demand. The shift toward minimally invasive, outpatient joint therapies supported by innovative products and care models is transforming treatment options for an aging population facing growing rates of osteoarthritis.
The details
Next-generation steroid combination formulations are offering dual benefits of pain relief and anti-inflammatory effects, reducing injection frequency while improving joint functionality. High molecular weight hyaluronic acid remains widely used for prolonged efficacy, while medium molecular weight variants are emerging as cost-effective alternatives. Ambulatory surgical centers are driving market growth with their efficient, lower-cost outpatient models, appealing to younger, active patients seeking same-day treatment.
- The Europe viscosupplementation market is projected to expand from $523.9 million in 2025 to $869.8 million by 2035.
- The market is expected to register a CAGR of 5.2% between 2025 and 2035.
The players
Zimmer Biomet
A leading player offering products like Durolane® and Gel-One®.
Sanofi
A major competitor with viscosupplementation products Synvisc® and Synvisc-One®.
Anika Therapeutics
A key player providing Orthovisc® and Monovisc® viscosupplementation treatments.
FidiaFarmaceutici
An innovative company offering the Hymovis® viscosupplementation product.
Bioventus
A viscosupplementation market participant focused on product innovation and outpatient care expansion.
What’s next
As the viscosupplementation market continues to evolve, key players will need to focus on regulatory alignment, post-market support, and strategic partnerships with ambulatory surgical centers and specialty clinics to capture the growing demand for innovative, outpatient joint therapies.
The takeaway
The convergence of demographic shifts, patient preferences, and technological advancements is transforming the viscosupplementation market in Europe, creating compelling opportunities for investment, expansion, and innovation over the next decade.
